Loading…
Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and seriously threatens the health of humans due to its high morbidity and mortality. Naringenin, as a natural flavanone, has shown various potential pharmacologi...
Saved in:
| Published in: | Biomolecules (Basel, Switzerland) Switzerland), 2020-12, Vol.10 (12), p.1644 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3 |
| container_end_page | |
| container_issue | 12 |
| container_start_page | 1644 |
| container_title | Biomolecules (Basel, Switzerland) |
| container_volume | 10 |
| creator | Chen, Zhen Chen, Pan Wu, Hao Shi, Rui Su, Weiwei Wang, Yonggang Li, Peibo |
| description | Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and seriously threatens the health of humans due to its high morbidity and mortality. Naringenin, as a natural flavanone, has shown various potential pharmacological activities against multiple pathological stages of COPD, but available studies are scattered and unsystematic. Thus, we combined literature review with network pharmacology analysis to evaluate the potential therapeutic effects of naringenin on COPD and predict its underlying mechanisms, expecting to provide a promising tactic for clinical treatment of COPD. |
| doi_str_mv | 10.3390/biom10121644 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9aada66f3ad346f69b4220814a1acd07</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9aada66f3ad346f69b4220814a1acd07</doaj_id><sourcerecordid>2469666249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3</originalsourceid><addsrcrecordid>eNpdks9rFDEcxQdRbKm9eZaAFw-u5tdkkouga62FpbtIBW_hO0lmm3VmsiaZLf3vTbu1bA2BhJdPHsnjVdVrgj8wpvDH1oeBYEKJ4PxZdUwpkTPasF_PD_ZH1WlKG1yGLJOyl9URYwxTVuPjajrbQT9B9mFEoUOXEP24dqMfESQEaBXD4FOR0FV0kAc3ZrTc3tNdiGi-XH1FXyA5i4qy8NlFyFN06IfbeXeDYLTo0uWbEH-j1TXEAUzow_r2VfWigz6504f1pPr57exq_n22WJ5fzD8vZoY3Ms8kM63EiihFgFtuMes4MU0traqNqV0rGkw6JhwIZRg2jhhBpWUYuOiUbNlJdbH3tQE2ehv9APFWB_D6XghxrSFmb3qnFYAFIToGlpXbQrWcUiwJBwLG4qZ4fdp7bad2cNaUKCL0T0yfnoz-Wq_DTjeNoLUgxeDdg0EMfyaXsi7RGtf3MLowJU15wzhmRMqCvv0P3YQpjiWqQgklhKBcFer9njIxpBRd9_gYgvVdPfRhPQr-5vADj_C_MrC_q4S2aw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2469666249</pqid></control><display><type>article</type><title>Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Chen, Zhen ; Chen, Pan ; Wu, Hao ; Shi, Rui ; Su, Weiwei ; Wang, Yonggang ; Li, Peibo</creator><creatorcontrib>Chen, Zhen ; Chen, Pan ; Wu, Hao ; Shi, Rui ; Su, Weiwei ; Wang, Yonggang ; Li, Peibo</creatorcontrib><description>Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and seriously threatens the health of humans due to its high morbidity and mortality. Naringenin, as a natural flavanone, has shown various potential pharmacological activities against multiple pathological stages of COPD, but available studies are scattered and unsystematic. Thus, we combined literature review with network pharmacology analysis to evaluate the potential therapeutic effects of naringenin on COPD and predict its underlying mechanisms, expecting to provide a promising tactic for clinical treatment of COPD.</description><identifier>ISSN: 2218-273X</identifier><identifier>EISSN: 2218-273X</identifier><identifier>DOI: 10.3390/biom10121644</identifier><identifier>PMID: 33302350</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Asthma ; Bioavailability ; Bronchitis ; Chemokines ; Chronic obstructive pulmonary disease ; COPD ; Cytokines ; Disease ; Drug dosages ; Inflammation ; Kinases ; Literature reviews ; Lung diseases ; Lungs ; mechanism ; Morbidity ; Naringenin ; Obstructive lung disease ; Oxidative stress ; Pathogenesis ; Pharmacology ; Proteins ; Respiratory diseases ; Review ; Tumor necrosis factor-TNF</subject><ispartof>Biomolecules (Basel, Switzerland), 2020-12, Vol.10 (12), p.1644</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3</citedby><cites>FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3</cites><orcidid>0000-0001-8328-806X ; 0000-0002-0339-3298</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2469666249/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2469666249?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,75096</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33302350$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Zhen</creatorcontrib><creatorcontrib>Chen, Pan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Shi, Rui</creatorcontrib><creatorcontrib>Su, Weiwei</creatorcontrib><creatorcontrib>Wang, Yonggang</creatorcontrib><creatorcontrib>Li, Peibo</creatorcontrib><title>Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology</title><title>Biomolecules (Basel, Switzerland)</title><addtitle>Biomolecules</addtitle><description>Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and seriously threatens the health of humans due to its high morbidity and mortality. Naringenin, as a natural flavanone, has shown various potential pharmacological activities against multiple pathological stages of COPD, but available studies are scattered and unsystematic. Thus, we combined literature review with network pharmacology analysis to evaluate the potential therapeutic effects of naringenin on COPD and predict its underlying mechanisms, expecting to provide a promising tactic for clinical treatment of COPD.</description><subject>Asthma</subject><subject>Bioavailability</subject><subject>Bronchitis</subject><subject>Chemokines</subject><subject>Chronic obstructive pulmonary disease</subject><subject>COPD</subject><subject>Cytokines</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Literature reviews</subject><subject>Lung diseases</subject><subject>Lungs</subject><subject>mechanism</subject><subject>Morbidity</subject><subject>Naringenin</subject><subject>Obstructive lung disease</subject><subject>Oxidative stress</subject><subject>Pathogenesis</subject><subject>Pharmacology</subject><subject>Proteins</subject><subject>Respiratory diseases</subject><subject>Review</subject><subject>Tumor necrosis factor-TNF</subject><issn>2218-273X</issn><issn>2218-273X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9rFDEcxQdRbKm9eZaAFw-u5tdkkouga62FpbtIBW_hO0lmm3VmsiaZLf3vTbu1bA2BhJdPHsnjVdVrgj8wpvDH1oeBYEKJ4PxZdUwpkTPasF_PD_ZH1WlKG1yGLJOyl9URYwxTVuPjajrbQT9B9mFEoUOXEP24dqMfESQEaBXD4FOR0FV0kAc3ZrTc3tNdiGi-XH1FXyA5i4qy8NlFyFN06IfbeXeDYLTo0uWbEH-j1TXEAUzow_r2VfWigz6504f1pPr57exq_n22WJ5fzD8vZoY3Ms8kM63EiihFgFtuMes4MU0traqNqV0rGkw6JhwIZRg2jhhBpWUYuOiUbNlJdbH3tQE2ehv9APFWB_D6XghxrSFmb3qnFYAFIToGlpXbQrWcUiwJBwLG4qZ4fdp7bad2cNaUKCL0T0yfnoz-Wq_DTjeNoLUgxeDdg0EMfyaXsi7RGtf3MLowJU15wzhmRMqCvv0P3YQpjiWqQgklhKBcFer9njIxpBRd9_gYgvVdPfRhPQr-5vADj_C_MrC_q4S2aw</recordid><startdate>20201208</startdate><enddate>20201208</enddate><creator>Chen, Zhen</creator><creator>Chen, Pan</creator><creator>Wu, Hao</creator><creator>Shi, Rui</creator><creator>Su, Weiwei</creator><creator>Wang, Yonggang</creator><creator>Li, Peibo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8328-806X</orcidid><orcidid>https://orcid.org/0000-0002-0339-3298</orcidid></search><sort><creationdate>20201208</creationdate><title>Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology</title><author>Chen, Zhen ; Chen, Pan ; Wu, Hao ; Shi, Rui ; Su, Weiwei ; Wang, Yonggang ; Li, Peibo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Asthma</topic><topic>Bioavailability</topic><topic>Bronchitis</topic><topic>Chemokines</topic><topic>Chronic obstructive pulmonary disease</topic><topic>COPD</topic><topic>Cytokines</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Literature reviews</topic><topic>Lung diseases</topic><topic>Lungs</topic><topic>mechanism</topic><topic>Morbidity</topic><topic>Naringenin</topic><topic>Obstructive lung disease</topic><topic>Oxidative stress</topic><topic>Pathogenesis</topic><topic>Pharmacology</topic><topic>Proteins</topic><topic>Respiratory diseases</topic><topic>Review</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Zhen</creatorcontrib><creatorcontrib>Chen, Pan</creatorcontrib><creatorcontrib>Wu, Hao</creatorcontrib><creatorcontrib>Shi, Rui</creatorcontrib><creatorcontrib>Su, Weiwei</creatorcontrib><creatorcontrib>Wang, Yonggang</creatorcontrib><creatorcontrib>Li, Peibo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Biomolecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Zhen</au><au>Chen, Pan</au><au>Wu, Hao</au><au>Shi, Rui</au><au>Su, Weiwei</au><au>Wang, Yonggang</au><au>Li, Peibo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology</atitle><jtitle>Biomolecules (Basel, Switzerland)</jtitle><addtitle>Biomolecules</addtitle><date>2020-12-08</date><risdate>2020</risdate><volume>10</volume><issue>12</issue><spage>1644</spage><pages>1644-</pages><issn>2218-273X</issn><eissn>2218-273X</eissn><abstract>Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and seriously threatens the health of humans due to its high morbidity and mortality. Naringenin, as a natural flavanone, has shown various potential pharmacological activities against multiple pathological stages of COPD, but available studies are scattered and unsystematic. Thus, we combined literature review with network pharmacology analysis to evaluate the potential therapeutic effects of naringenin on COPD and predict its underlying mechanisms, expecting to provide a promising tactic for clinical treatment of COPD.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33302350</pmid><doi>10.3390/biom10121644</doi><orcidid>https://orcid.org/0000-0001-8328-806X</orcidid><orcidid>https://orcid.org/0000-0002-0339-3298</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2218-273X |
| ispartof | Biomolecules (Basel, Switzerland), 2020-12, Vol.10 (12), p.1644 |
| issn | 2218-273X 2218-273X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_9aada66f3ad346f69b4220814a1acd07 |
| source | PubMed (Medline); Publicly Available Content (ProQuest) |
| subjects | Asthma Bioavailability Bronchitis Chemokines Chronic obstructive pulmonary disease COPD Cytokines Disease Drug dosages Inflammation Kinases Literature reviews Lung diseases Lungs mechanism Morbidity Naringenin Obstructive lung disease Oxidative stress Pathogenesis Pharmacology Proteins Respiratory diseases Review Tumor necrosis factor-TNF |
| title | Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T04%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Naringenin%20as%20a%20Promising%20Treatment%20Option%20for%20COPD%20Based%20on%20Literature%20Review%20and%20Network%20Pharmacology&rft.jtitle=Biomolecules%20(Basel,%20Switzerland)&rft.au=Chen,%20Zhen&rft.date=2020-12-08&rft.volume=10&rft.issue=12&rft.spage=1644&rft.pages=1644-&rft.issn=2218-273X&rft.eissn=2218-273X&rft_id=info:doi/10.3390/biom10121644&rft_dat=%3Cproquest_doaj_%3E2469666249%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-83cb8091991a4d4d03f41c758d95cc5eb6701f36ea69c30ce1c628d30a46f98b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2469666249&rft_id=info:pmid/33302350&rfr_iscdi=true |